Diabetes center CEO: New Eli Lilly drug is worthy opponent for Novo Nordisk's Ozempic

Allan Flyvbjerg, CEO of Steno Diabetes Center in Copenhagen, says Eli Lilly’s tirzepatide has proved itself a fierce challenger to Novo Nordisk’s newest generation of diabetes drugs.


According to the CEO of an influential diabetes center in Copenhagen, Novo Nordisk has gained a worthy opponent within the diabetes indication in the form of Eli Lilly’s Mounjaro (tirzepatide), which was recently approved in the US.

Allan Flyvbjerg, CEO of Steno Diabetes Center, said the following to industry media Dagens Pharma:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs